文献速递细菌感染、耐药与抗菌药物

唑利氟达星单用及与六种抗菌药联用对淋球菌的体外活性与耐药演化

In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本研究以WHO F、O、V、X四株淋球菌参考株为对象,采用棋盘法、时间-杀菌曲线和耐药选择实验,评估first-in-class螺吡嘧啶三酮类新药唑利氟达星单用及与头孢曲松、头孢克肟、大观霉素、庆大霉素、四环素、西他霉素或西他沙星联用的体外活性与耐药选择。结果显示唑利氟达星单用或联用均快速抑制淋球菌生长,耐药突变选择频率低且联用后进一步降低,耐药株均携带GyrB D429N、K450T或K450N突变。

要点

  • 唑利氟达星单用或与六种淋病治疗抗菌药联用均快速抑制淋球菌生长。
  • 四环素或西他霉素与唑利氟达星联用可显著降低唑利氟达星的体外杀菌速率。
  • 耐药突变选择频率低,联用后进一步降低;耐药株携带GyrB D429N、K450T或K450N突变。

核心结论

  • 唑利氟达星单用或与性传播感染治疗抗菌药联用可快速杀灭淋球菌,耐药发生频率低,作为口服单药治疗及双药治疗组成部分均有前景。

研究设计与样本

  • 体外研究,采用国际淋球菌参考株WHO F(野生型)、WHO O、WHO V和WHO X(不同抗菌药物耐药谱),通过棋盘法、时间-杀菌曲线分析和耐药选择研究评估唑利氟达星单用或联用。

主要发现

  • 唑利氟达星单用或与全部六种抗菌药联用对全部受试菌株均显示快速生长抑制。
  • 时间-杀菌曲线分析提示四环素或西他霉素与唑利氟达星联用可显著降低唑利氟达星的体外杀菌速率。
  • 唑利氟达星单用时耐药突变选择频率低,所有抗菌药联用后进一步降低。
  • 全部耐药突变株均携带GyrB D429N、K450T或K450N突变,导致唑利氟达星MIC为0.5-4 mg/L。

临床怎么用

  • 提示唑利氟达星可作为淋病口服单药治疗或双药治疗的候选药物,联用可能降低耐药发生风险。
  • 四环素或西他霉素与唑利氟达星联用可能降低其杀菌速率,联合方案选择需权衡。

局限性

  • 研究为体外实验,仅使用四株国际参考菌株,结论需临床研究验证。
  • 原文提及计划于2019年开展评估唑利氟达星治疗无并发症淋病疗效与安全性的III期试验,尚未提供临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Resistance in Neisseria gonorrhoeae to all gonorrhoea therapeutic antimicrobials has emerged. Novel therapeutic antimicrobials are imperative and the first-in-class spiropyrimidinetrione zoliflodacin appears promising. Zoliflodacin could be introduced in dual antimicrobial therapies to prevent the emergence and/or spread of resistance. We investigated the in vitro activity of and selection of resistance to zoliflodacin alone and in combination with six gonorrhoea therapeutic antimicrobials against N. gonorrhoeae. METHODS: The international gonococcal reference strains WHO F (WT) and WHO O, WHO V and WHO X (strains with different AMR profiles) were examined. Zoliflodacin was evaluated alone or combined with ceftriaxone, cefixime, spectinomycin, gentamicin, tetracycline, cethromycin or sitafloxacin in chequerboard assays, time-kill curve analysis and selection-of-resistance studies. RESULTS: Zoliflodacin alone or in combination with all six antimicrobials showed rapid growth inhibition against all examined strains. The time-kill curve analysis indicated that tetracycline or cethromycin combined with zoliflodacin can significantly decrease the zoliflodacin kill rate in vitro. The frequency of selected zoliflodacin-resistance mutations was low when evaluated as a single agent and further reduced for all antimicrobial combinations. All resistant mutants contained the GyrB mutations D429N, K450T or K450N, resulting in zoliflodacin MICs of 0.5-4 mg/L. CONCLUSIONS: Zoliflodacin, alone or in combination with sexually transmitted infection therapeutic antimicrobials, rapidly kills gonococci with infrequent resistance emergence. Zoliflodacin remains promising for gonorrhoea oral monotherapy and as part of dual antimicrobial therapy with low resistance emergence potential. A Phase III trial evaluating efficacy and safety of zoliflodacin for uncomplicated gonorrhoea treatment is planned in 2019.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Foerster S, Drusano G, Golparian D, et al. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. J Antimicrob Chemother. 2019. PMID: 31730160. doi:10.1093/jac/dkz376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。